Patanjali Plans To Raise Rs 1,000 Crore To Fund Expansion
Baba Ramdev-backed Patanjali Ayurved Ltd., India's second largest consumer goods maker, plans to raise up to Rs 1,000 crore as it looks to boost production and launch new products.
The company is looking at borrowing funds from banks, said S K Tijarawala, a spokesperson of Patanjali.
The maker of Dantkanti toothpaste and Keshkanti shampoo said it will reach a production capacity of 50,000 crore units by the end of this year and plans to double it over the next three years. The company has 50 manufacturing units across the country, including large food parks, Tijarawala told BloombergQuint over the phone. The company wants to scale up production at its existing facilities in Maharashtra, Assam, Andhra Pradesh, Madhya Pradesh, Noida, Uttar Pradesh and Uttrakhand, he said.
Patanjali replaced ITC Ltd. as India's second largest maker of fast moving consumer goods with a revenue of more than Rs 10,500 crore in the year ended March. More than a third of it came from five products: cow's ghee, toothpaste, ayurvedic medicines, shampoos and soaps. It continues to enter newer categories.
Also Read: Products That Helped Patanjali Become India's No. 2 Consumer Goods Maker
Earlier, the company announced that it will enter branded apparel and will launch its collection in the summer of 2018 for women and kids. It also launched a security services firm that will enlist guards from Patanjali's 11 lakh yoga centres across India.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.